ราคา CelsiusCEL

0.6 soon buy buy😍

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.

Celsius to Distribute $127 Million to Creditors Amid Ongoing Bankruptcy Proceedings Celsius, the embattled cryptocurrency lender, has announced plans to distribute $127 million to its creditors. However, the payout is subject to certain conditions and eligibility criteria. Eligible creditors will receive their share in Bitcoin (BTC), Ethereum (ETH), or US dollars (USD). Notably, recipients who opt for BTC or ETH must have a Coinbase account. Otherwise, they will automatically receive USD after November 9, 2024. The payout primarily benefits individuals classified under the Illiquid Recovery Rights category within Celsius's bankruptcy plan. A portion of the funds will also be allocated to address unforeseen issues. Former Celsius CEO Alex Mashinsky Faces Fraud Charges Meanwhile, Alex Mashinsky, Celsius's former CEO, is facing charges for market manipulation and fraud, including alleged misconduct related to the CEL token. A judge recently dismissed his attempt to dismiss two fraud charges. If convicted on all seven counts, Mashinsky could face up to 115 years in prison. His trial is scheduled for January 2025. The Aftermath of the 2022 Crypto Winter Celsius's bankruptcy is a lingering consequence of the 2022 crypto winter, which resulted in significant investor losses. While the payout provides some relief, it is a modest consolation compared to the substantial losses incurred. The crypto industry's ongoing struggles are underscored by high-profile cases like Celsius and BlockFi. In related news, law firms involved in crypto cases, such as Kirkland & Ellis, have reportedly earned substantial fees, totaling $120 million. Next Steps and Implications For creditors, the payout offers a measure of relief, albeit insufficient to compensate for their losses. As Mashinsky's trial approaches, the situation remains fluid. The crypto industry's path to recovery remains uncertain, with this development representing only a small step forward. Key Takeaways: - Celsius to distribute $127 million to creditors - Payout subject to eligibility criteria and conditions - Former CEO Alex Mashinsky faces fraud charges, with trial set for January 2025 - Crypto industry continues to grapple with aftermath of 2022 crypto winter

Celsius to Distribute $127 Million to Creditors Amid Ongoing Bankruptcy Proceedings Celsius, the embattled cryptocurrency lender, has announced plans to distribute $127 million to its creditors. However, the payout is subject to certain conditions and eligibility criteria. Eligible creditors will receive their share in Bitcoin (BTC), Ethereum (ETH), or US dollars (USD). Notably, recipients who opt for BTC or ETH must have a Coinbase account. Otherwise, they will automatically receive USD after November 9, 2024. The payout primarily benefits individuals classified under the Illiquid Recovery Rights category within Celsius's bankruptcy plan. A portion of the funds will also be allocated to address unforeseen issues. Former Celsius CEO Alex Mashinsky Faces Fraud Charges Meanwhile, Alex Mashinsky, Celsius's former CEO, is facing charges for market manipulation and fraud, including alleged misconduct related to the CEL token. A judge recently dismissed his attempt to dismiss two fraud charges. If convicted on all seven counts, Mashinsky could face up to 115 years in prison. His trial is scheduled for January 2025. The Aftermath of the 2022 Crypto Winter Celsius's bankruptcy is a lingering consequence of the 2022 crypto winter, which resulted in significant investor losses. While the payout provides some relief, it is a modest consolation compared to the substantial losses incurred. The crypto industry's ongoing struggles are underscored by high-profile cases like Celsius and BlockFi. In related news, law firms involved in crypto cases, such as Kirkland & Ellis, have reportedly earned substantial fees, totaling $120 million. Next Steps and Implications For creditors, the payout offers a measure of relief, albeit insufficient to compensate for their losses. As Mashinsky's trial approaches, the situation remains fluid. The crypto industry's path to recovery remains uncertain, with this development representing only a small step forward. Key Takeaways: - Celsius to distribute $127 million to creditors - Payout subject to eligibility criteria and conditions - Former CEO Alex Mashinsky faces fraud charges, with trial set for January 2025 - Crypto industry continues to grapple with aftermath of 2022 crypto winter